Does society place special value on end of life treatments?

Care at the End of Life: An Economic Perspective

Volumn , Issue , 2016, Pages 155-166

  Shah, Koonal ^a,b  

^a Office of Health Economics   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009073726     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-28267-1_11     Document Type: Chapter

References (29)

1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of healthcare programmes. Oxford University Press, Oxford
2. Culyer AJ (1997) Maximising the health of the whole community. In: New B (ed) Rationing: talk and action in health care. BMJ/King's Fund, London
3. Dolan P, Shaw R, Tsuchiya A, Williams A (2005) QALY maximisation and people's preferences: a methodological review of the literature. Health Econ 14:197-208
4. NICE (2013) Guide to the methods of technology appraisal 2013. National Institute for Health and Care Excellence, London
5. Department of Health (2003) Tackling health inequalities: a programme for action. Department of Health, London
6. Williams A (1996) QALYs and ethics: a health economist's perspective. Soc Sci Med 43(12):1795-1804
7. NICE (2008) Social value judgements: principles for the development of NICE guidance, 2nd edn. National Institute for Health and Care Excellence, London
8. Rawlins MD, Culyer AJ (2004) National Institute for Clinical Excellence and its value judgments. BMJ 329:224-227
9. Shah KK (2009) Severity of illness and priority setting in healthcare: a review of the literature. Health Policy 93:77-84
10. Abel Olsen J (2013) Priority preferences: "end of life" does not matter, but total life does. Value Health 16(6):1063-1066
11. Baker R, McHugh N, Mason H, Currie G, Donaldson C (2011) Valuing end of life technologies, investigating the existence of a 'cancer premium' and methodological questions for health economics virtuous. Paper presented at the Health Economists' Study Group meeting, Bangor, 29 June-1 July 2011
12. Linley WG, Hughes DA (2013) Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ 22(8):948-964
13. Pennington M, Baker R, Brouwer W, Mason H, Donaldson C, The EuroVaQ Team (2015) Comparing WTP values of different types of QALY gain elicited from the general public. Health Econ 24(3):280-293
14. Pinto-Prades JL, Sanchez-Martinez FI, Corbacho B, Baker R (2014) Valuing QALYs at the end of life. Soc Sci Med 113:5-14
15. Rowen D, Brazier J, Mukuria C, Keetharuth A, Risa Hole A, Tsuchiya A, Whyte S, Shackley P (2014) Update: eliciting societal preferences for weighting QALYs according to burden of illness, size of gain and end of life. EEPRU Research Report. Universities of Sheffi eld and York
16. Shah KK, Tsuchiya A, Wailoo AJ (2014) Valuing health at the end of life: an empirical study of public preferences. Eur J Health Econ 15:389-399
17. Shah K, Tsuchiya A, Wailoo A (2015) Valuing health at the end of life: a stated preference discrete choice experiment. Soc Sci Med 124:48-56
18. Skedgel C, Wailoo A, Akehurst R (2015) Societal preferences for distributive justice in the allocation of healthcare resources: a latent class discrete choice experiment. Med Decis Making 35:94-105
19. NICE (2009) Appraising life-extending, end of life treatments. National Institute for Health and Care Excellence, London
20. NICE (2009) End of life treatments: summary response to consultation. National Institute for Health and Care Excellence, London
21. NICE (2009) Appraising life-extending, end of life treatments. Revised in July 2009. National Institute for Health and Care Excellence, London
22. Rawlins M, Barnett D, Stevens A (2010) Pharmacoeconomics: NICE's approach to decisionmaking. Br J Clin Pharmacol 70(3):346-349
23. Collins M, Latimer N (2013) NICE's end of life decision making scheme: impact on population health. BMJ 346:f1363
24. Shah KK, Cookson R, Culyer AJ, Littlejohns P (2013) NICE's social value judgements about equity in health and health care. Health Econ Policy Law 8(2):145-165
25. Trowman R, Chung H, Longson C, Littlejohns P, Clark P (2011) The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales. Clin Cancer Res 17:4930-4935
26. Scottish Government (2013) Response to the Health and Sport Committee inquiry into access to new medicines. Available via: http://www.scottish.parliament.uk/S4_HealthandSportCommittee/ Inquiries/Scottish_Government_Response_-_Access_into_New_Medicines.pdf Accessed 6 Aug 2015
27. Green C (2011) Looking for the 'values' to inform value-based pricing: a review of the empirical ethics (equity) evidence! Paper presented at the Health Economists' Study Group meeting, Bangor, 29 June-1 July 2011
28. NICE (2014) Value based assessment of health technologies. National Institute for Health and Care Excellence, London
29. Schwappach DLB (2002) Resource allocation, social values and the QALY: a review of the debate and empirical evidence. Health Expect 5:210-222